VSL Pharmaceuticals Inc., Leadiant Biosciences Inc. and Alfasigma USA Inc.

Allegations that VSL Pharmaceuticals, Leadiant Biosciences and Alfasigma USA misrepresented the clinical effectiveness of VSL#3, leading consumers to overpay for the product.

VSL Pharmaceuticals Inc., Leadiant Biosciences Inc. and Alfasigma USA Inc. agreed to pay $20 million to settle a class action lawsuit alleging these companies misrepresented the clinical effectiveness of VSL#3, leading consumers to overpay for the product. The class includes anyone who bought VSL#3 for personal use between June 1, 2016, and June 19, 2019. Class members can claim their payment with or without proof of purchase. Class members without proof of purchase may claim $20 for one unit per household. Class members with proof of purchase may claim $20 per unit for up to 40 units per household, a maximum of $800. If the total value of valid claims is less than the available funds, the per-unit payment may be increased up to three times, to $60 per unit. If the total claims exceed the available funds, the per-unit payment will be reduced pro rata. The claim deadline is Oct. 20, 2026.

• Anyone who bought VSL#3 for personal use in the United States between June 1, 2016, and June 19, 2019.